4D Molecular Therapeutics(FDMT) - 2023 Q4 - Annual Results

Exhibit 99.1 4DMT Reports Full Year 2023 Financial Results and Operational Highlights EMERYVILLE, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today reported full year 2023 financial results and provided operational highlights. "2023 was a transformative year for 4DMT with incredible progress across our pro ...